The CXXC finger 5 protein is required for DNA damage-induced p53 activation

Science in China, Series C: Life Sciences

Volumn 52, Issue 6, 2009, Pages 528-538

  Zhang, Min ^a   Wang, Rui Peng ^a   Wang, Yan Yi ^b   Diao, Fei Ci ^a   Lu, Fei ^a   Gao, Dong ^a   Chen, Dan Ying ^a   Zhai, Zhong He ^a   Shu, Hong Bing ^b  

^a PEKING UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; ATM; DNA damage; p53

Indexed keywords

ATAXIA TELANGIECTASIA;

ANTINEOPLASTIC AGENT; ATM PROTEIN; CARRIER PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; ETOPOSIDE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RINF PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; ZINC FINGER PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL CYCLE; DNA DAMAGE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; RNA INTERFERENCE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; ETOPOSIDE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

EID: 70149092565     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-009-0083-7     Document Type: Article

References (46)

1. Vousden K H. p53: death star. Cell, 2000, 103(5): 691-694.
2. Sharpless N E, DePinho R A. p53: good cop/bad cop. Cell, 2002, 110(1): 9-12.
3. Lombard D B, Chua K F, Mostoslavsky R, et al. DNA repair, genome stability, and aging. Cell, 2005, 120(4): 497-512.
4. Aylon Y, Oren M. Living with p53, dying of p53. Cell, 2007, 130(4): 597-600.
5. Marine J C, Francoz S, Maetens M, et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ, 2006, 13(6): 927-934.
6. Toledo F, Wahl G M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer, 2006, 6(12): 909-923.
7. Vousden K H, Lane D P. p53 in health and disease. Nat Rev Mol Cell Biol, 2007, 8(4):275-283.
8. Borkowska E, Binka-Kowalska A, Constantinou M, et al. P53 mutations in urinary bladder cancer patients from Central Poland. J Appl Genet, 2007, 48(2): 177-183.
9. Caulin C, Nguyen T, Lang G A, et al. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest, 2007, 117(7): 1893-1901.
10. Gottschalg E, Scott G B, Burns P A, et al. Potassium diazoacetate-induced p53 mutations in vitro in relation to formation of O6-carboxymethyl- and O6-methyl-2′-deoxyguanosine DNA adducts: relevance for gastrointestinal cancer. Carcinogenesis, 2007, 28(2): 356-362.
11. Kouidou S, Malousi A, Kyventidis A, et al. G: C > A: T mutations and potential epigenetic regulation of p53 in breast cancer. Breast Cancer Res Treat, 2007, 106(3): 351-360.
12. Queille S, Luron L, Spatz A, et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis, 2007, 28(3): 724-731.
13. Canman C E, Lim D S, Cimprich K A, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 1998, 281(5383): 1677-1679.
14. Lee J H, Paull T T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science, 2004, 304(5667): 93-96.
15. Lee J H, Paull T T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science, 2005, 308(5721): 551-554.
16. Hartley K O, Gell D, Smith G C, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell, 1995, 82(5): 849-856.
17. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 1995, 268(5218): 1749-1753.
18. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell, 1996, 86(1): 159-171.
19. Harper J W, Elledge S J. The DNA damage response: ten years after. Mol Cell, 2007, 28(5): 739-745.
20. Lavin M F, Kozlov S. ATM activation and DNA damage response. Cell Cycle, 2007, 6(8): 931-942.
21. Rai R, Peng G, Li K, et al. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics, 2007, 4(2): 99-106.
22. Siliciano J D, Canman C E, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997, 11(24): 3471-3481.
23. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science, 1998, 281(5383): 1674-1677.
24. Khanna K K, Keating K E, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet, 1998, 20(4): 398-400.
25. Shieh S Y, Ikeda M, Taya Y, et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 1997, 91(3): 325-334.
26. Corcoran C A, Huang Y, Sheikh M S. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol Ther, 2004, 3(8): 721-725.
27. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature, 2004, 429(6987): 86-92.
28. Marchler-Bauer A, Anderson J B, Derbyshire M K, et al. CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res, 2007, 35 (Database issue): D237-240.
29. Krude T, Jackman M, Pines J, et al. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell, 1997, 88(1): 109-119.
30. Shu H B, Takeuchi M, Goeddel D V. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci USA, 1996, 93(24): 13973-13978.
31. Ward I M, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem, 2001, 276(51): 47759-47762.
32. Matsuda A, Suzuki Y, Honda G, et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene, 2003, 22(21): 3307-3318.
33. Xu L G, Wang Y Y, Han K J, et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell, 2005, 19(6): 727-740.
34. Hsu I C, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis, 1993, 14(5): 987-992.
35. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature, 1993, 361(6413): 647-650.
36. Anderson S C, Johnson D E, Harris M P, et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res, 1998, 4(7): 1649-1659.
37. Meplan C, Mann K, Hainaut P. Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J Biol Chem, 1999, 274(44): 31663-31670.
38. Hendrikse A S, Hunter A J, Keraan M, et al. Effects of low dose irradiation on TK6 and U937 cells: induction of p53 and its role in cell-cycle delay and the adaptive response. Int J Radiat Biol, 2000, 76(1): 11-21.
39. Grob T J, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ, 2001, 8(12): 1213-1223.
40. Walerych D, Kudla G, Gutkowska M, et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem, 2004, 279(47): 48836-48845.
41. Enokimura N, Shiraki K, Kawakita T, et al. Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway. Anticancer Drugs, 2005, 16(8): 837-844.
42. Kastan M B, Zhan Q, el-Deiry W S, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 1992, 71(4): 587-597.
43. Eppenberger U, Kueng W, Eppenberger-Castori S, et al. Molecular factors determine primary and secondary therapy of breast carcinoma. Ther Umsch, 1997, 54(8): 451-456.
44. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 1998, 95(1): 5-8.
45. Seoane J, Le H V, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 2002, 419(6908): 729-734.
46. Chipuk J E, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303(5660): 1010-1014.